Literature DB >> 19057459

Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections.

David Y Hyun1, Edward O Mason, Andrea Forbes, Sheldon L Kaplan.   

Abstract

The outcome of patients who were treated with oral trimethoprim-sulfamethoxazole or oral clindamycin after hospitalization at Texas Children's Hospital for community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections was compared. No significant differences were observed in the percentage of patients who returned to the emergency center or clinics because of worsening or incomplete resolution of the infected site.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19057459     DOI： 10.1097/INF.0b013e3181826e5e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  16 in total

1.  Catalysis and sulfa drug resistance in dihydropteroate synthase.

Authors:  Mi-Kyung Yun; Yinan Wu; Zhenmei Li; Ying Zhao; M Brett Waddell; Antonio M Ferreira; Richard E Lee; Donald Bashford; Stephen W White
Journal:  Science       Date:  2012-03-02       Impact factor: 47.728

2.  Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.

Authors:  Loren G Miller; Robert S Daum; C Buddy Creech; David Young; Michele D Downing; Samantha J Eells; Stephanie Pettibone; Rebecca J Hoagland; Henry F Chambers
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

3.  Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children.

Authors:  J Chase McNeil; Kristina G Hulten; Sheldon L Kaplan; Edward O Mason
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 4.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Comparative effectiveness of antibiotic treatment strategies for pediatric skin and soft-tissue infections.

Authors:  Derek J Williams; William O Cooper; Lisa A Kaltenbach; Judith A Dudley; David L Kirschke; Timothy F Jones; Patrick G Arbogast; Marie R Griffin; C Buddy Creech
Journal:  Pediatrics       Date:  2011-08-15       Impact factor: 7.124

6.  Binding Isotope Effects for para-Aminobenzoic Acid with Dihydropteroate Synthase from Staphylococcus aureus and Plasmodium falciparum.

Authors:  Christopher F Stratton; Hilda A Namanja-Magliano; Scott A Cameron; Vern L Schramm
Journal:  ACS Chem Biol       Date:  2015-08-27       Impact factor: 5.100

7.  Impact of Systemic Antibiotics on Staphylococcus aureus Colonization and Recurrent Skin Infection.

Authors:  Patrick G Hogan; Marcela Rodriguez; Allison M Spenner; Jennifer M Brenneisen; Mary G Boyle; Melanie L Sullivan; Stephanie A Fritz
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

8.  Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece.

Authors:  George D Katopodis; Ioanna N Grivea; Angeliki J Tsantsaridou; Spyros Pournaras; Efi Petinaki; George A Syrogiannopoulos
Journal:  BMC Infect Dis       Date:  2010-12-13       Impact factor: 3.090

9.  Management of pediatric skin abscesses in pediatric, general academic and community emergency departments.

Authors:  Brigitte M Baumann; Christopher J Russo; Daniel Pavlik; Tara Cassidy-Smith; Naomi Brown; Alfred Sacchetti; Lisa M Capano-Wehrle; Rakesh D Mistry
Journal:  West J Emerg Med       Date:  2011-05

Review 10.  Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin.

Authors:  Christian Eckmann; M Dryden
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.